Commonly leads to cardiovascular disease and other complications such as anaemia, disordered bone mineral metabolism and calcification of blood vessels
Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) - uses serum creatinine, age, sex and adjusted for body surface area (in very small/large patients)
Modification of diet in Renal Disease (MDRD) Equation - also uses serum creatinine, age, sex and race
Estimated GFR calculated using CKD-EPI or MDRD is normalised to a standard body surface area of 1.73m2. If using eGFR to calculate drug doses in patients at extremes of body weight or for drugs with a narrow therapeutic index correct eGFR to "actual GFR" using the equation: Actual GFR = (eGFR x BSA/1.73)
Some medicines can cause kidney problems/damage – often referred to as nephrotoxic medicines
The use of medicines in patients with reduced renal function (AKI or CKD) can also give rise to problems for a number of reasons including: pharmacokinetic (ADME) changes including reduced renal excretion of a drug or its metabolites which may cause toxicity, sensitivity to some drugs is increased even if elimination is unimpaired, many side-effects are tolerated poorly by patients with renal impairment, some drugs are not effective when renal function is reduced
When to use eCrCl rather than eGFR to determine renal dose adjustments
Creatinine clearance or absolute glomerular filtration rate should be used to adjust drug doses in patients with a BMI less than 18 kg/m2 or greater than 40 kg/m2
The Cockcroft and Gault formula is the preferred method for estimating renal function in elderly patients aged 75 years and over
The use of CKD-EPI may be appropriate in patients over 75 years, however muscle mass should be taken into consideration. Using CKD-EPI to calculate eGFR has the potential to overestimate renal function progressively as age increases, which can increase the risk of adverse effects due to higher than recommended doses being prescribed